Natalizumab in the pediatric MS population: results of the Italian registry

BACKGROUND: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghezzi, Angelo, Moiola, Lucia, Pozzilli, Carlo, Brescia-Morra, Vincenzo, Gallo, Paolo, Grimaldi, Luigi Maria Edoardo, Filippi, Massimo, G., Giancarlo Comi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583752/
https://www.ncbi.nlm.nih.gov/pubmed/26407848
http://dx.doi.org/10.1186/s12883-015-0433-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583752/
https://www.ncbi.nlm.nih.gov/pubmed/26407848
http://dx.doi.org/10.1186/s12883-015-0433-y

Ejemplares similares